Unknown

Dataset Information

Optimal sequential enrichment designs for phase II clinical trials.


ABSTRACT: In the early phase development of molecularly targeted agents (MTAs), a commonly encountered situation is that the MTA is expected to be more effective for a certain biomarker subgroup, say marker-positive patients, but there is no adequate evidence to show that the MTA does not work for the other subgroup, that is, marker-negative patients. After establishing that marker-positive patients benefit from the treatment, it is often of great clinical interest to determine whether the treatment benefit extends to marker-negative patients. The authors propose optimal sequential enrichment (OSE) designs to address this practical issue in the context of phase II clinical trials. The OSE designs evaluate the treatment effect first in marker-positive patients and then in marker-negative patients if

SUBMITTER: Zang Y 

PROVIDER: S-EPMC5138118 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature